ThirdLaw Molecular LLC
"Any sufficiently advanced technology is
indistinguishable from magic."
- Arthur C. Clarke
We are developing a powerful new molecular recognition technology that will enable the sensitive and selective detection of any biological threat, infection, biomarker of a health condition, environmental toxin, or disease, anywhere, at a low cost.
It is an arduous process to identify suitable antibodies for diagnostic devices. Antibodies are large, fragile proteins requiring a cold chain and careful handling to maintain their activity. They are difficult to manufacture with good quality control and suffer from batch-to-batch variability. Antibodies have high manufacturing costs. Antibodies are astounding molecules that have evolved over billions of years to detect and protect us from disease. Antibodies did not evolve to be robust components in point-of-care diagnostic devices.
Spiroligomers are synthetic molecules made from modular, cyclic, stereochemically pure building blocks that display sidechains like amino acids. We join these building blocks together through pairs of amide bonds to create robust ladder molecules with the programmable display of side chains from their backbone. At ThirdLaw Molecular LLC, we have synthesized more than 2.5 million spiroligomer nanostructures large enough to wrap around protein surfaces and recognize them selectively with high affinity. Spiroligomers act as artificial antibodies, capable of binding proteins with specificity. We are incorporating spiroligomers into lateral flow assays and advanced, robust, multiplexed, sensitive and selective sensor-coupled diagnostic devices where conventional antibodies are inadequate.
We are developing spiroligomer nanostructures to advance beyond monoclonal antibodies in point-of-care diagnostic tests.